ErVimmune is proud to be part of the new set of 47 companies selected to receive European Innovation Council (EIC) funding, combining grants and...
Here is the LinkedIn post from Paris Saclay Cancer Cluster: click here
ErVimmune Partners with Servier to Identify Regulatory Mechanisms of Endogenous Retroviruses in Tumors
Download the press release LYON, FRANCE October 11, 2023 – ErVaccine Technologies (now ErVimmune), a French biotechnology company developing...
Download the presse release Lyon, France – June 15, 2023 – ErVaccine Technologies, a French biotechnology company developing next-generation...
A new review article in Science Advances 2023 – TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Download the press release Lyon, France – February 23, 2023 – ErVaccine Technologies, a French biotech company developing next-generation...
ErVimmune closes a €4.5 million financing round and prepares to start clinical trial with its first therapeutic cancer vaccine in 2023
ErVaccine is developing a therapeutic vaccine and cell therapy technology potentially applicable to many types of cancers First vaccine candidate...
Paola Bonaventura, project leader at ErVaccine Technologies, has been giving a talk entitled “Human Endogenous Retrovirus (HERVs) Represent a...
Stéphane Depil, founder and CEO of ErVaccine Technologies, will give a talk entitled “Human Endogenous Retrovirus Represent a Source of Shared...
ErVaccine Technologies, in collaboration with Centre Leon Berard hospital / Cancer Research Center of Lyon, is thrilled to announce the selection of...
Medical research and development, in particular the development of new families of tumour antigens.
Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.
> Publications & abstracts
> Recent news
> Legal notice
> About us
> Join us
28 RUE LAENNEC
69008 LYON FRANCE
+33 6 67 67 44 97